EUCTR2019-000645-12-NL进行中（未招募）1 期
A Double-Blind, Placebo-Controlled, Cross-over Phase II Study to Evaluate the Effect of a 6-week Elafibranor (120mg) treatment administered once daily on hepatic lipid composition in subjects with Nonalcoholic Fatty Liver (NAFL).
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- GENFIT SA
- 入组人数
- 16
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Males or post-menopausal females aged from 40-75 years inclusive at first Screening Visit. (Post-menopausal defined as: subject should be surgically sterilized at least 6 months or no spontaneous menses for at least 1 year prior to screening)
- •2. Must provide signed written informed consent and agrees to comply with the study protocol.
- •3. Liver fat percentage IHL = 5% (as measured with 1H-MRS)
- •4. 25.0 = BMI = 38.0 kg/m2
- •5. Stable dietary habits and physical activity pattern (over 3 months prior to Screening Visit)
- •6. Subject agrees not to change dietary habits and physical activity pattern, to follow diet and lifestyle recommendations and not to consume or use illicit drugs during the study up to end of treatment.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range 8
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 8
排除标准
- •Medical history:
- •1. Documented weight loss of more than 5% during the 6-month period prior to Screening Visit
- •2. Contra-indications for MRI/MRS
- •3. Known history of Type 1 and 2 diabetes
- •4. Known chronic heart failure (Grade I to IV of New York Heart Association classification)
- •5. History of clinically significant acute cardiac event within 6 months prior to Screening Visit such as: stroke, transient ischemic attack, or coronary heart disease (angina pectoris, myocardial infarction, revascularization procedures)
- •6. Uncontrolled hypertension despite optimal antihypertensive therapy
- •7. Other well documented causes of chronic liver disease according to standard diagnostic procedures.
- •8. Symptoms of clinical depression
- •9. Other concurrent medical (e.g., immunological, neoplastic, endocrine, hematological, gastrointestinal or neurological) or psychiatric condition, which, in the opinion of the Investigator, would place the subject at increased risk, preclude obtaining voluntary consent/assent or compliance with required study procedures, or would confound the objectives of study
- •10. Known hypersensitivity to the investigation product or any of its formulation excipients
- •Concomitant medications and lifestyle:
- •11. Fibrates are not permitted from 8 weeks before Screening up to end of treatment. Subjects taking statins or ezetimibe prior to Screening Visit 1 may participate if the dose has been stable for 3 months prior to Screening Visit 1 and no dose adjustments are anticipated
- •12. Currently taking drugs that can induce steatosis/steatohepatitis including, but not restricted to: corticosteroids (parenteral & oral chronic administration only), amiodarone (Cordarone), tamoxifen (Nolvadex), and methotrexate (Rheumatrex, Trexall), which are not permitted 30 days prior to Screening and up to end of treatment
- •13. Subjects receiving thiazoledinediones (glitazones [pioglitazone, rosiglitazone])
- •14. Currently taking any medication that could interfere with study medication absorption, distribution, metabolism, or excretion or could lead to induction or inhibition of microsomal enzymes, e.g., indomethacin, which are not permitted from Randomization until end of treatment
- •15. Any medication use known to interfere with glucose homeostasis/metabolism
- •16. Smoking
- •17. Current or recent history (<5years) of significant alcohol consumption. For men, significant consumption is typically defined as higher than 30 g pure alcohol per day. For women, it is typically defined as higher than 20 g pure alcohol per day
- •18. Subjects who have donated blood or blood products within the previous month prior to screening or who plan to donate blood or blood products at any time during the trial and in the month following the end of the study
- •19. Is participating in any other study and have received any other investigational drug or device within 30 days prior to Screening or are taking part in a non-medication study which, in the opinion of the Investigator, would interfere with study compliance or outcome assessments
- •20. Subjects who cannot be contacted in case of emergency
- •In addition to the above criteria, subject should not present any of the following biological exclusion criteria:
- •21. Positive anti-human immunodeficiency virus (HIV) antibody
- •22. Positive hepatitis B surface antigen
- •23. Positive hepatitis C Virus (HCV) antibody
- •24. Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) >5 x upper limit of normal (ULN)
- •25. Conjugated bilirubin > 1.50
研究者
相似试验
已完成
2 期
A Double-Blind, Placebo-Controlled, Cross-over Phase II Study to Evaluate the Effect of a 6-week Elafibranor (120mg) treatment administered once daily on hepatic lipid composition in subjects with Nonalcoholic Fatty Liver (NAFL).Non-alcoholic fatty liver1001965410000546fatty liverNL-OMON47978GENFIT16
终止
1 期
A Double-Blind, Randomized, Placebo-Controlled Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of CT-868 in Healthy Overweight/Obese Participants and in Patients withType 2 Diabetes MellitusType 2 Diabetes MellitusACTRN12618001988246Carmot Therapeutics87
暂停
2 期
Global Phase 2 clinical trial to Evaluate Safety And Efficacy Of US-APR2020 In Subjects With Chronic Kidney Disease Stage IVCTRI/2022/11/047767Kibow Biotech Inc
进行中（未招募）
1 期
Effectiveness and safety of riociguat in patients with sclerosis of the skiEUCTR2014-001353-16-GBBayer AG121
尚未招募
3 期
A Randomised, Double-Blind, Placebo-Controlled Phase 3 Clinical Trial to Assess the Efficacy and Safety of Lebrikizumab in Combination With Topical Corticosteroids in Adult and Adolescent Patients With Moderate-To-Severe Atopic Dermatitis That Are Not Adequately Controlled With Cyclosporine or For Whom Cyclosporine is Not Medically Advisable.eczemainflammation of the skin10014982NL-OMON52148Almirall18